BRAF V600 mutations – leading to mitogen-activated protein kinase (MAPK) pathway activation – can be found in 5–15% of low-grade gliomas, including PXA (60–80%), gangliogliomas (20–70%), pilocytic astrocytomas (10%), and less frequently in GBM (approximately 3%) [23]. The gene discussed is BRAF; the disease is central nervous system cancer.